Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Genmab A/S - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
GMAB
Nasdaq
2830
www.genmab.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Genmab A/S
High Growth Tech Stocks To Watch In November 2024
- Nov 8th, 2024 7:03 am
Genmab AS (GMAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Pipeline ...
- Nov 7th, 2024 7:20 am
Genmab Announces Financial Results for the First Nine Months of 2024
- Nov 6th, 2024 4:02 pm
Genmab to Present at Jefferies London Healthcare Conference
- Nov 5th, 2024 6:11 pm
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
- Nov 5th, 2024 5:00 pm
Genmab A/S (GMAB): Leading Innovation in Antibody Therapeutics
- Oct 17th, 2024 12:57 pm
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock?
- Oct 16th, 2024 1:44 pm
Is Genmab (GMAB) Stock Undervalued Right Now?
- Oct 15th, 2024 1:40 pm
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
- Oct 15th, 2024 10:25 am
Genmab A/S (GMAB): Among The Stocks With Biggest Upside Potential According to Hedge Funds
- Oct 9th, 2024 7:32 pm
GMAB or INCY: Which Is the Better Value Stock Right Now?
- Oct 8th, 2024 3:40 pm
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround
- Oct 8th, 2024 1:35 pm
Major Shareholder Announcement
- Oct 4th, 2024 5:55 pm
Is Genmab A/S (GMAB) One of the Best Revenue Growth Stocks to Buy According to Analysts?
- Sep 30th, 2024 4:40 pm
Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Sep 26th, 2024 7:17 pm
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
- Sep 15th, 2024 12:45 pm
Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Sep 10th, 2024 8:06 pm
Genmab A/S (GMAB): One of the Best Affordable Stocks Under $40 According to Short Sellers
- Aug 30th, 2024 9:49 pm
Top High Growth Tech Stocks To Watch In August 2024
- Aug 28th, 2024 12:05 pm
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
- Aug 26th, 2024 4:26 pm
Scroll